RxDoctor Payments Data

Shweta Joshi, MD

Gastroenterology · Williamsburg, VANPI 1427093152

Payments from drug & device makers

$2,246in general payments, 2019–2025

Across 92 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$645
  • Johnson & Johnson$266
  • Takeda Pharmaceuticals U.S.A., Inc.$185
  • Exact Sciences$180
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$166
  • Janssen Scientific Affairs, LLC$139
  • plus $665 from 13 others

What the payments were for

  • Food & beverage$2,07792%
  • Education$1698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,246 in reported general payments places this provider in the 35th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$128,526
Medicare patients
572
Services billed
978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$350,759
VemlidyTenofovir Alafenamide13$18,371
LinzessLinaclotide20$17,696
Budesonide ErBudesonide14$15,888
TrulancePlecanatide11$7,926
MovantikNaloxegol Oxalate14$6,401
Mesalamine12$5,812
Famotidine161$2,716
Omeprazole219$2,007
Budesonide DrBudesonide13$1,658
Pantoprazole Sodium129$945
Esomeprazole Magnesium27$679
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl18$314
Metronidazole11$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$266$350,75913 claims
GileadVemlidy$18$18,37113 claims
AbbVieLinzess$645$17,69620 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$166$7,92611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Williamsburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →